BLAINJECTIONINJECTABLEPriority Review
Approved
Dec 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
64
Data completeness
7/8 — Comprehensive
Priority Review
BLINCYTO (blinatumomab) by Amgen is cd19-directed cd3 t-cell engager that binds to cd19 expressed on the surface of cells of b-lineage origin and cd3 expressed on the surface of t-cells. Approved for older with: cd19-positive b-cell precursor acute lymphoblastic leukemia (all) in first, second complete remission with minimal residual disease (mrd) greater than, equal to 0 and 5 more indications. First approved in 2014.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BLINCYTO (blinatumomab) is a bispecific antibody that engages T cells to target and destroy CD19-expressing B cells. It is indicated for acute lymphoblastic leukemia (ALL), mixed phenotype acute leukemia, diffuse large B-cell lymphoma, chronic myeloid leukemia, non-Hodgkin lymphoma, and minimal residual disease. The mechanism leverages dual specificity to redirect T-cell cytotoxicity against malignant B-cell populations.
$2.0MPart D
PeakBLINCYTO is at peak lifecycle stage with modest Part D spending, indicating a niche market presence requiring specialized hematology expertise and focused commercial execution.
Mechanism of Action
CD19-directed CD3 T-cell engager that binds to CD19 expressed on the surface of cells of B-lineage origin and CD3 expressed on the surface of T-cells. It activates endogenous T-cells by connecting CD3 in the T-cell receptor (TCR) complex with CD19 on benign and malignant B-cells. Blinatumomab…
Worked on BLINCYTO at Amgen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.